Comparative study of paradoxical and classical psoriasis: what are clinical and therapeutic differences?
作者信息
Demir Yusuf, Ak Tumay, Temiz Sera Nur Yucesoy, Engin Burhan
机构信息
Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
出版信息
Arch Dermatol Res. 2024 May 24;316(6):216. doi: 10.1007/s00403-024-03052-7.
PMID:38787400
Abstract
摘要
相似文献
1
Comparative study of paradoxical and classical psoriasis: what are clinical and therapeutic differences?
Arch Dermatol Res. 2024 May 24;316(6):216. doi: 10.1007/s00403-024-03052-7.
2
Erythrodermic psoriasis and secukinumab: Our clinical experience.
Dermatol Ther. 2018 Jul;31(4):e12607. doi: 10.1111/dth.12607. Epub 2018 Apr 16.
3
Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
Br J Dermatol. 2019 Nov;181(5):1106-1107. doi: 10.1111/bjd.18174. Epub 2019 Aug 20.
4
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
J Am Acad Dermatol. 2019 Sep;81(3):857-859. doi: 10.1016/j.jaad.2019.05.007. Epub 2019 May 10.
5
Guselkumab (Tremfya) for psoriasis.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):179-180.
6
Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
J Dermatol. 2019 Mar;46(3):e112-e113. doi: 10.1111/1346-8138.14619. Epub 2018 Aug 27.
7
Brodalumab versus ustekinumab in psoriasis.
Dermatol Ther. 2016 Sep;29(5):298. doi: 10.1111/dth.12323. Epub 2015 Dec 2.
8
Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther. 2017 Jul 17;59(1525):118-119.
9
COVID-19 and psoriasis: Recommendation for patients on regular infliximab therapy.
Dermatol Ther. 2020 Nov;33(6):e14472. doi: 10.1111/dth.14472. Epub 2020 Nov 9.
10
Trajectories of switching to optimise efficacy and minimising risks in patients with moderate-to-severe plaque psoriasis: results from the PsoReal registry.
Arch Dermatol Res. 2024 May 25;316(6):263. doi: 10.1007/s00403-024-02967-5.
本文引用的文献
1
Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2022 Jun;55(11):1379-1388. doi: 10.1111/apt.16883. Epub 2022 Mar 21.
2
Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature.
Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):791-800. doi: 10.1016/j.ad.2018.04.003. Epub 2018 Jun 11.
3
PASI90 response: the new standard in therapeutic efficacy for psoriasis.
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):645-8. doi: 10.1111/jdv.12817. Epub 2014 Nov 4.
Zotero 插件